Mineralys director Peterson receives equity awards

The RSUs and option shares vest over three years, subject to continued service through each applicable vesting date.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. director Kristine Peterson received 12,400 restricted stock units and a stock option award covering 16,600 common shares on October 19, 2026. Each RSU represents a contingent right to receive one common share upon vesting; one-third vest annually over three years. The option shares vest monthly over three years, with 1/36 vesting each month, and the exercise price is $20.92 per share. Both awards are subject to continued service through each applicable vesting date.

Insider Trade Summary

Grant/Award: 29,000 shares

Grant/Award 2 txns

Insider Peterson Kristine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F2	16,600	$0.00	$0.00
Grant/Award	Common Stock F1	12,400	$0.00	$0.00

Holdings After Transaction: Stock Option — 16,600 contracts (Direct); Common Stock — 12,400 shares (Direct)

Footnotes (2)

1. F1. Consists of restricted stock units (RSUs) granted for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of three years, with 1/3rd of the RSUs vesting on each one-year anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.
2. F2. The shares underlying the stock option vest in monthly installments over a period of three years, with 1/36th of the underlying shares vesting on each monthly anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

Key Figures

Restricted stock units granted: 12,400 RSUs Common shares underlying option award: 16,600 shares Option exercise price: $20.92 per share +2 more

5 metrics

Restricted stock units granted 12,400 RSUs Awarded October 19, 2026

Common shares underlying option award 16,600 shares Awarded October 19, 2026

Option exercise price $20.92 per share Stock option award dated October 19, 2026

RSU vesting schedule 1/3 annually over three years Subject to continued service through each applicable vesting date

Option share vesting schedule 1/36 monthly over three years Subject to continued service through each applicable vesting date

Key Terms

restricted stock units (RSUs), contingent right, exercise price

3 terms

restricted stock units (RSUs) financial

"Consists of restricted stock units (RSUs) granted for no additional cash consideration"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

contingent right financial

"each of which represents a contingent right to receive one share of common stock upon vesting"

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Kristine Peterson receive from MLYS?

On October 19, 2026, Mineralys Therapeutics director Kristine Peterson received 12,400 RSUs and a stock option award covering 16,600 common shares, with an exercise price of $20.92 per share.

Were Kristine Peterson’s MLYS RSUs granted for cash?

The 12,400 RSUs were granted for no additional cash consideration; each represents a contingent right to receive one common share upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 05:35 PM EDT Accepted by SEC EDGAR 10/20/2026 - 05:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Kristine

(Last) (First) (Middle)

C/O MINERALYS THERAPEUTICS, INC.

150 N. RADNOR CHESTER ROAD, SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/19/2026		A		12,400	A	$0	12,400(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$20.92	10/19/2026		A		16,600		(2)	10/19/2036	Common Stock	16,600	$0	16,600	D

Explanation of Responses:

1. Consists of restricted stock units (RSUs) granted for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of three years, with 1/3rd of the RSUs vesting on each one-year anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

2. The shares underlying the stock option vest in monthly installments over a period of three years, with 1/36th of the underlying shares vesting on each monthly anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

Remarks:

	/s/ Jeffrey A. Munsie, attorney-in-fact	10/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)